logo-loader

Orgenesis to conduct clinical trials for Type 1 diabetes treatment in Russia

Published: 11:41 24 Nov 2015 EST

Orgenesis to conduct clinical trials for Type 1 diabetes treatment in Russia
Orgenesis is a company that is committed to developing a cure for Type 1 Diabetes

Orgenesis (OTCMKTS:ORGS), a cell therapy and regenerative medicine company, signed a collaboration agreement with Russian company, Biosequel LLC on conducting clinical trials in Russia.

The collaboration will start with the opening of the new Yauza Medical Center on November 24, the Germantown, Maryland-based company said in a statement.

"Orgenesis is on the cutting edge of medical development in driving the industry towards a practical cure for Type 1 Diabetes and we are honored to work with them in Russia to facilitate the human clinical trials in this country," the company cites Dr. Vitaly Shabadash, Biosequel founder and practicing Israeli physician, as saying.

Orgenesis is a company that is committed to developing a cure for Type 1 Diabetes.

The company has developed and patented a novel technology called "cellular trans-differentiation" that turns an insulin-dependent patient's own liver cells into functional insulin producing cells.

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

21 minutes ago